drugset
Drugs / Abelacimab
last change Apr 2026 re-read 2 minutes ago

Abelacimab

also known as MAA868

Monoclonal antibody targets F11 via inhibition

Developed for
atrial fibrillation · pulmonary embolism · venous thromboembolism · stroke disorder · thrombotic disease
Investigated by
Novartis Pharmaceuticals · Anthos Therapeutics, Inc. · Covance

Trials 7 · a red edge is where a trial was stopped

today NCT05712200 · Ph 3 NCT05171075 · Ph 3 NCT05171049 · Ph 3 NCT04755283 · Ph 2 NCT04213807 · Ph 2 NCT03398434 · Ph 2 NCT03393481 · Ph 2
2019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT04755283 Feb 2021 → Feb 2024 overdue atrial fibrillation, stroke disorder Anthos Therapeutics, Inc. Active not recruiting No outcome recorded
Phase 2 NCT04213807 Dec 2019 → Dec 2020 atrial fibrillation Anthos Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT03398434 Oct 2018 → Nov 2019 atrial fibrillation Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 2 NCT03393481 Oct 2018 → Jan 2020 thrombotic disease Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 33 trials
Phase 3 NCT05712200 Dec 2022 → Dec 2027 expected atrial fibrillation Anthos Therapeutics, Inc. Recruiting No outcome recorded
Phase 3 NCT05171075 Sep 2022 → Apr 2026 pulmonary embolism, venous thromboembolism Anthos Therapeutics, Inc. Terminated No outcome recorded
Phase 3 NCT05171049 May 2022 → Feb 2026 pulmonary embolism, venous thromboembolism Anthos Therapeutics, Inc. Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Abelacimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT05171049 ↗
3

NCT05171075 ↗

NCT05712200 ↗

NCT04755283 ↗
Known as MAA868 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04213807 ↗
2

NCT03393481 ↗

NCT03398434 ↗
Action Inhibit “binds to the inactive form of factor XI and blocks its activation” PMID 39842011 ↗ Jan 2025
Modality Monoclonal antibody “Abelacimab is a fully human monoclonal antibody” PMID 39842011 ↗ Jan 2025
Route Subcutaneous “single administration, subcutaneous” NCT03393481 ↗
Target F11 “binds to the inactive form of factor XI and blocks its activation” PMID 39842011 ↗ Jan 2025